Evidence map›Paper›PMID 34011502›Full record

ReviewBMJ global health2021

Novel vaccine safety issues and areas that would benefit from further research.

Daniel A Salmon, Paul Henri Lambert, Hanna M Nohynek, Julianne Gee, Umesh D Parashar, Jacqueline E Tate, Annelies Wilder-Smith, Kenneth Y Hartigan-Go, Peter G Smith, Patrick Louis F Zuber

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Dengue Vaccines: An Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Review
  6. [Vaccinations].Der Internist · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel A SalmonGlobal Disease Epidemiology and Control, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA dsalmon1@jhu.edu.ORCID 0000-0002-1035-4422
Paul Henri LambertCentre of Vaccinology, University of Geneva, Geneva, GE, Switzerland.
Hanna M NohynekInfectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Uusimaa, Finland.
Julianne GeeDivision of Healthcare Quality Promotion, National Center of Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, Georgia, USA.
Umesh D ParasharDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.
Jacqueline E TateDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.
Annelies Wilder-SmithLondon School of Hygiene & Tropical Medicine, London, London, UK.
Kenneth Y Hartigan-GoAsian Institute of Management, Makati City, Philippines.
Peter G SmithMRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, London, UK.
Patrick Louis F ZuberEssential Medicines and Health Products, Organisation Mondiale de la Sante, Geneve, Switzerland.ORCID 0000-0002-8966-5054

Funding

Medical Research Council MR/R010161/1World Health Organization 001
6 · The paper itself

Abstract

Vaccine licensure requires a very high safety standard and vaccines routinely used are very safe. Vaccine safety monitoring prelicensure and postlicensure enables continual assessment to ensure the benefits outweigh the risks and, when safety problems arise, they are quickly identified, characterised and further problems prevented when possible. We review five vaccine safety case studies: (1) dengue vaccine and enhanced dengue disease, (2) pandemic influenza vaccine and narcolepsy, (3) rotavirus vaccine and intussusception, (4) human papillomavirus vaccine and postural orthostatic tachycardia syndrome and complex regional pain syndrome, and (5) RTS,S/adjuvant system 01 malaria vaccine and meningitis, cerebral malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons learned that can be useful for addressing some of the potential safety issues that will inevitably arise with new vaccines.

Indexed as

MalariaRotavirus VaccinesFemaleHumansRotavirus Vaccinesdenguemalariapublic healthvaccines

Identifiers

PMID34011502
PMCPMC8137224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.